Caris Life Sciences, a precision oncology firm backed by Sixth Street and JH Whitney, is targeting a valuation of up to $5.3bn in its upcoming US initial public offering, as appetite for new listings gathers pace amid improving market sentiment, according to a report by Reuters.
